BioClock: Bright Light Therapy for Depressive Disorders
NCT05958940 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 231
Last updated 2025-01-09
Summary
Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response.
This clinical trial has three main goals:
* Optimize the administration of BLT for patients with depressive episodes.
* Gain a deeper understanding of the treatment mechanisms.
* Determine which patients benefit the most from the treatment.
The specific objectives are as follows:
* Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT.
* Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes.
* Identify patient characteristics and behaviours that can predict treatment outcomes.
* Develop a brain model to better understand the impact of BLT on the brain.
In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups:
* Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands.
* LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day.
* LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light.
The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.
Conditions
- Depression, Unipolar
- Depression, Bipolar
Interventions
- PROCEDURE
-
Bright Light Therapy
In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
- DEVICE
-
Blue Light Blocking Glasses
Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
Sponsors & Collaborators
-
Eindhoven University of Technology
collaborator OTHER -
Geestelijke Gezondheidszorg Eindhoven (GGzE)
collaborator OTHER -
Chrono@Work B.V.
collaborator UNKNOWN -
Universiteit Leiden
lead OTHER
Principal Investigators
-
Niki Antypa, PhD · Leiden University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-08
- Primary Completion
- 2026-09-30
- Completion
- 2026-12-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Circadian Effects of Escitalopram
NCT01214044 ·Status: COMPLETED ·Phase: NA
-
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 ·Status: COMPLETED ·Phase: PHASE2
-
BPL-003 Efficacy and Safety in Treatment Resistant Depression
NCT05870540 ·Status: COMPLETED ·Phase: PHASE2
-
Behavioral Insomnia Therapy For Those With Insomnia and Depression
NCT00620789 ·Status: UNKNOWN ·Phase: NA
-
A Study in Adult Patients With Major Depressive Disorder
NCT00795821 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study in Prevention of Re-emergence of Depression Symptoms
NCT01299272 ·Status: COMPLETED ·Phase: PHASE3
-
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
NCT05537584 ·Status: COMPLETED ·Phase: PHASE4
-
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
NCT01407094 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)
NCT01185977 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder
NCT05568823 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
NCT07120880 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
NCT00917059 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
NCT01724112 ·Status: COMPLETED ·Phase: PHASE2
-
Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression
NCT00106197 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
NCT04937829 ·Status: COMPLETED ·Phase: PHASE1
-
AZD6765 for Treatment Resistant Depression
NCT00491686 ·Status: COMPLETED ·Phase: PHASE2
-
Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression
NCT00177294 ·Status: COMPLETED ·Phase: PHASE4
-
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05061706 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
NCT00759395 ·Status: COMPLETED ·Phase: PHASE2
-
In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells
NCT05887310 ·Status: UNKNOWN
-
EXOMIND (BTL-699-2) for Improvement of Mental Well-being
NCT06899646 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240 ·Status: RECRUITING ·Phase: PHASE2
-
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01435759 ·Status: COMPLETED ·Phase: PHASE2